Fig. 1
From: Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series
Clinical course of patients receiving mepolizumab for CF with evidence of type 2 inflammation. Red and yellow arrows represent episodes of CF exacerbations associated with lung function decline, requiring intravenous or oral antibiotics, respectively. Orange triangle represents mepolizumab initiation. The yellow lines across the top of each figure represent periods of systemic corticosteroid use